Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya reported progress in the commercial rollout of its Salix platform in the U.S., with full integration across five Tanner Health hospitals and increasing scan volumes beginning to generate fee-per-scan revenue. Integration and onboarding work at Northeast Georgia Health System and Cone Health advanced, with all three foundation customers targeted to be live and generating Salix Coronary Anatomy and Plaque revenues from the start of the 2027 financial year.
The company completed its Salix Coronary Flow module with commercial features and high measured accuracy, and it is undergoing final clinical data validation ahead of an FDA 510(k) submission. Artrya also advanced preparations for its multi-centre SAPPHIRE Study across six major U.S. health systems, strengthened its U.S. leadership and board, joined the S&P/ASX All Ordinaries Index, and ended the quarter with a pro forma cash position of $76.6 million, underpinning its expansion plans.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on coronary artery disease. It is commercialising Salix, an AI-powered cloud platform that provides real-time, point-of-care assessment and management of coronary artery disease, with an emphasis on the U.S. hospital market and large cardiology networks.
Average Trading Volume: 487,655
Technical Sentiment Signal: Buy
Current Market Cap: A$652M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.